Medtronic invests in Pi-Cardia for TAVR
Analysis based on 9 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The investment strengthens Medtronic's structural heart portfolio and positions it to capture growth in the complex TAVR market, likely boosting investor confidence and supporting its stock price. Pi-Cardia Ltd. gains financial backing and global distribution through Medtronic, accelerating adoption of its ShortCut device and enhancing its valuation.
Medtronic plc announced a strategic investment in Pi-Cardia Ltd. Ltd., a privately held medical device company specializing in leaflet modification technologies for structural heart disease. The investment, up to $80 million, includes an option for Medtronic to acquire Pi-Cardia Ltd. upon achieving predefined milestones, with an estimated upfront acquisition price of up to $210 million plus potential earn-out payments. Medtronic is expected to become the exclusive global commercial distributor of Pi-Cardia Ltd.'s ShortCut device in 2027, expanding access across the United States, Europe, Japan, and other markets. ShortCut is the first United States — Food and Drug Administration-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction, demonstrating successful leaflet splitting in pivotal trials. The transaction is subject to regulatory approval and customary closing conditions. Medtronic's shares rose nearly 7% in pre-market trading following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard